danazol has been researched along with cytarabine in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (17.65) | 18.7374 |
| 1990's | 4 (23.53) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hotta, T | 1 |
| Buzaid, AC; Garewal, HS; Greenberg, BR | 1 |
| Lutz, D | 1 |
| Grisold, W; Lutz, D; Mamoli, B; Mokrusa, W; Weber, R | 1 |
| Haase, D; Hehlmann, R; Hild, F; Lengfelder, E; Simon, M | 1 |
| Cosson, A; Fenaux, P; Grardel, N; Lepelley, P; Poulain, S; Preudhomme, C | 1 |
| Diehl, V; Dimski, T; Lathan, B; Pantke, B; Schinköthe, T; Staib, P; Voliotis, D; Wiedenmann, S | 1 |
| Haferlach, C; Haferlach, T; Schnittger, S; Weisser, M | 1 |
| Aul, C; Balleisen, L; Beelen, D; Berdel, WE; Braess, J; Büchner, T; Eimermacher, H; Gale, RP; Giagounidis, A; Görlich, D; Grüneisen, A; Haferlach, C; Haferlach, T; Hehlmann, R; Heinecke, A; Hiddemann, W; Kern, W; Köpcke, W; Krug, U; Lengfelder, E; Ludwig, WD; Maschmeyer, G; Müller-Tidow, C; Rasche, H; Reichle, A; Sauerland, MC; Schliemann, C; Schnittger, S; Serve, H; Spiekermann, K; Staib, P; Stelljes, M; Thiel, E; Wörmann, BJ | 1 |
3 review(s) available for danazol and cytarabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Management of myelodysplastic syndromes].
Topics: Bone Transplantation; Cholecalciferol; Colony-Stimulating Factors; Cytarabine; Danazol; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Humans; Immunologic Factors; Isotretinoin; Myelodysplastic Syndromes | 1990 |
Management of myelodysplastic syndromes.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Danazol; Glucocorticoids; Humans; Isotretinoin; Myelodysplastic Syndromes; Pyridoxal Phosphate; Pyridoxine; Tretinoin | 1986 |
3 trial(s) available for danazol and cytarabine
| Article | Year |
|---|---|
Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes.
Topics: Acute Disease; Antibiotics, Antineoplastic; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytarabine; Danazol; Disease Progression; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation; Hematopoietic Stem Cells; Humans; Karyotyping; Leukemia, Myeloid; Leukemia, Myelomonocytic, Chronic; Life Tables; Myelodysplastic Syndromes; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Quinine; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53; Vault Ribonucleoprotein Particles | 1998 |
Prognosis in adult AML is precisely predicted by the DISC-assay using the chemosensitivity-index Ci.
Topics: Adult; Aminoglutethimide; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cell Survival; Cytarabine; Danazol; Drug Screening Assays, Antitumor; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Predictive Value of Tests; Prognosis; Prospective Studies; Regression Analysis; Remission Induction; Survival Analysis; Tamoxifen; Vidarabine | 1999 |
Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia.
Topics: Adult; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Danazol; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Stem Cell Transplantation; Survival Rate; Tamoxifen; Transplantation, Autologous; Treatment Outcome; Young Adult | 2016 |
11 other study(ies) available for danazol and cytarabine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Various induction therapies in older patients with acute myeloid leukemias].
Topics: Aclarubicin; Adolescent; Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Danazol; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthacenes; Tamoxifen | 1985 |
[Acute myelomonocytic and monoblastic leukemia with polyradicular symptoms].
Topics: Abducens Nerve; Adult; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cerebral Hemorrhage; Cerebrospinal Fluid; Cranial Nerve Diseases; Cytarabine; Danazol; Demyelinating Diseases; Facial Paralysis; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Meningism; Methotrexate; Middle Aged; Spinal Nerve Roots; Tamoxifen | 1985 |
[Complete remission in acute promyelocytic leukemia. The advantages of all-trans-retinoic acid compared to conventional chemotherapy].
Topics: Adult; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Danazol; Drug Evaluation; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Remission Induction; Tamoxifen; Time Factors; Tretinoin | 1994 |
Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 3; Cohort Studies; Cytarabine; Danazol; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Karyotyping; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Prognosis; Survival Analysis; Tamoxifen; Translocation, Genetic | 2007 |